EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review

Шапина, М. В.; Nanaeva, B. A.; Варданян, А В

doi:10.33878/2073-7556-2019-18-3-119-130

Cited by 3 publications

(3 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В связи с этим эффективность устекинумаба, выраженная в показателях CDAI -100, CDAI<150 и QALY, несколько отличается на разных режимах терапии. Необходимо отметить, что терапию устекинумабом следует начинать в режиме применения 1/12 недель и только при отсутствии должного ответа на биотерапию возможно увеличение дозы и переходом на режим 1/8 недель [9,12].…”

Section: анализ эффективностиunclassified

“…Последствием применения иммуносупрессоров служит высокий риск развития злокачественных новообразований и угнетение функции костного мозга [8]. В связи с этим клиническая потребность в лечении оставалась неудовлетворенной, что послужило стимулом создания инновационных видов терапии, в частности генно-инженерных биологических препаратов (ГИБП) [9].…”

Section: Introductionunclassified

“…В настоящее время в терапии БК в соответствии с российскими и международными рекомендациями применяются следующие классы ГИБП: ингибиторы фактора некроза опухоли альфа (ФНО-α), антагонисты интегриновых рецепторов и ингибиторы интерлейкинов (ИЛ) 12/23 [2,4,9]. Возможности применения ингибиторов ФНО-α ограничены: у 30% пациентов ответ на терапию недостаточен либо со временем теряется [5].…”

Section: Introductionunclassified

See 2 more Smart Citations

Pharmacoeconomic Evaluation of Biological Drugs in the Crohn’s Disease Treatment in the Russian Federation

Serpik¹,

Kulikov²,

Веселов³

et al. 2020

Pharmacoeconom T&P

View full text Add to dashboard Cite

Section: анализ эффективностиunclassified

Section: Introductionunclassified

See 1 more Smart Citation

Pharmacoeconomic Evaluation of Biological Drugs in the Crohn’s Disease Treatment in the Russian Federation

Serpik¹,

Kulikov²,

Веселов³

et al. 2020

Pharmacoeconom T&P

View full text Add to dashboard Cite

Efficacy and safety of ustekinumab therapy in patients with Crohn’s disease. Real clinical practice

et al. 2022

View full text Add to dashboard Cite

Introduction.The results of registrational clinical trials (CTs) and real clinical practice do not always correlate. The task of practitioners is to find optimal approaches to the therapy of Crohn’s disease, based on the analysis of clinical trials and real-world data.Aim. To make a retrospective assessment of the efficacy and tolerability of UST therapy in patients with moderate to severe CD in real clinical practice.Materials and methods. A total of 88 patients with CD were included in the study to evaluate the efficacy and safety of UST. Among the patients, men accounted for 48.9%, women – 51.1%, the average age was 36.4 ± 4.8 years, the disease duration was 7.8 ± 2.1 years. 67.1% of patients with moderate CD in the form of ileocolitis (82.9%) had a stenosing (26.1%) and penetrating (50.0%) form of the disease. 95.4% of patients received prior immunosuppressive therapy.Results. After inductive therapy with UST, clinical response and clinical remission within 8 weeks were recorded in 86 (97.7%) patients with CD. After 26 weeks, 58 (65.9%) patients achieved clinical remission, 28 (31.8%) patients with CD and all patients who responded to UST therapy maintained clinical response. Crohn’s Disease Activity Index (CDAI) decreased from 445.8 ± 50.4 to 134.6 ± 21.4 points. Clinically significant endoscopic improvement was reported in 25 (40.3%) of 62 patients, endoscopic response in 14 (22.6%) patients, endoscopic remission in 18 (29.0%). After 26 weeks, CDAI decreased from 7.8 ± 1.8 to 2.9 ± 1.2 points, after 52 weeks it decreased from 445.8 ± 50.4 to 141.6 ± 28.2. Steroid-free remission in CD patients accounted for 68.2%. 1-year survival of UST therapy was 97.7%, 2-year survival was 95.5%.Conclusions. The observation demonstrated the high efficacy of the drug in induction and maintenance therapy in the cohort of patients with severe to moderate CD resistant to disease-modifying and genetically engineered biological drugs.

show abstract

Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis

Mugruza-Vassallo

Pomazanova

Durleshter³

2021

Medicinskij alfavit

View full text Add to dashboard Cite

Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of the analysis of the case histories of patients with moderate-to-severe and severe forms of psoriasis and concomitant pathology – inflammatory bowel diseases (Clinical Dermatovenerologic Dispensary, Krasnodar, Russia). The analysis of 16 case histories of patients with moderate-to-severe and severe psoriasis has been carried out, where one can see the clinical and practical significance of the combined pathology – psoriasis and inflammatory bowel diseases. From the analysis, one can conclude that there is a direct relationship between the severity of the course of the skin pathological process and the development of intestinal diseases, as well as the influence of ustekinumab on the course of combined pathology – psoriasis, ulcerative colitis and Crohn’s disease.

show abstract

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE (review

Cited by 3 publications

References 58 publications

Pharmacoeconomic Evaluation of Biological Drugs in the Crohn’s Disease Treatment in the Russian Federation

Pharmacoeconomic Evaluation of Biological Drugs in the Crohn’s Disease Treatment in the Russian Federation

Efficacy and safety of ustekinumab therapy in patients with Crohn’s disease. Real clinical practice

Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis

Contact Info

Product

Resources

About